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1. Introduction
   Magnetic microspheres are supramolecular particles that are 
small enough to circulate through capillaries without producing 
embolic occlusion (<4 毺m) but are sufficiently susceptible 
(ferromagnetic) to be captured in micro vessels and dragged 
in to the adjacent tissues by magnetic fields of 0.5-0.8 tesla. 
Magnetic drug delivery by particulate carriers is a very efficient 
method of delivering a drug to a localized disease site. In 
magnetic targeting, a drug or therapeutic radioisotope is bound 
to a magnetic compound, injected into a patient’s blood stream, 
and then stopped with a powerful magnetic field in the target 
area. Magnetic carriers receive their magnetic responsiveness to 
a magnetic field from incorporated materials such as magnetite, 
iron, nickel, cobalt, neodymium-iron-boron or samarium-
cobalt[1]. Magnetic microsphere were developed to minimize 
renal clearance and to increase target site specificity
2. History of magnetic targeting
3. What is ferrofluid?
   Ferrofluid (FF), is a colloidal suspension of single-domain 
magnetic particles, with dimensions of about 10 nm, dispersed in 
a liquid carrier[8]
4. Factors related to ferrofluid
   Factors: 1. Size of the particles in ferrofluid. 2. Surface 
characteristics of particles. 3. Concentration of the ferrofluid. 4. 
Volume of the ferrofluid. 5. Reversibility and strength of drug/
ferrofluid binding (desorption characteristics). 6. Access to 
the organism (infusion route). 7. Duration or rate of injection/
infusion. 8. Geometry, strength and duration of the magnetic 
field application[10]. 9. Ferro fluids are optically isotropic but, 
in the presence of an external magnetic field, exhibit induced 
birefringence[11].
   Wetting of particular substrates can also induce birefringence 
in thin FF layers. In order to avoid agglomeration magnetic 
Novel drug delivery system aims to deliver the drug at a rate directed by the needs of the body 
during the period of treatment, and target the active entity to the site of action. A number of novel 
drug delivery systems have emerged encompassing various routes of administration, to achieve 
controlled and targeted drug delivery, magnetic micro carriers being one of them.
   Magnetic microsphere is newer approach in pharmaceutical field. Magnetic microspheres 
as an alternative to traditional radiation methods which use highly penetrating radiation that 
is absorbed throughout the body. Its use is limited by toxicity and side effects. The aim of the 
specific targeting is to enhance the efficiency of drug delivery & at the same time to reduce 
the toxicity & side effects. This kind of delivery system is very much important which localises 
the drug to the disease site. In this larger amount of freely circulating drug can be replaced by 
smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic responses 
to a magnetic field from incorporated materials that are used for magnetic microspheres are 
chitosan, dextran etc. magnetic microspheres can be prepared from a variety of carrier material. 
One of the most utilized is serum albumin from human or other appropriate species. Drug release 
from albumin microspheres can be sustained or controlled by various stabilization procedures 
generally involving heat or chemical cross-linking of the protein carrier matrix.
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particles need coating. So they are classified in two ways: 
Classification of ferrofluids: 1. Surfacted ferrofluids: if the coating 
is a surfactant molecule. 2. Ionic ferrofluids: if it is an electric 
shell.
5. Classification of drug targeting
   
   Classification I: First-order targeting, Second-order targeting, 
Third-order targeting. Classification II: Organ targeting, 
Cellular targeting, Sub cellular targeting. Classification III: 
Passive targeting, Active targeting, Physiochemical targeting. 
Classification IV: Site-directed targeting, Site-avoidance 
targeting. Classification V. Biochemical targeting, Biomechanical 
targeting, Biophysical targeting, Bioadhesive targeting. 
Classification VI: Carrier-dependent, Carrier-independent[26]
  Considerable attention has been paid to the use of polymer 
microspheres for the sustained release of various drugs and 
the targeting of therapeutic agents to their site of action. 
Biodegradable poly-D, L-lactic acid (PDLLA) microspheres can 
be efficiently taken up by macrophages and M cells[27].  
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Figure 1. Principle of magnetic drug targeting.
Table 1.
History of magnetic carriers.
S.No. Scientist Work in past
1 Gilchrist published a seminar paper in 1956 on the selective inductive heating of lymph nodes after injection of 20.100 nm 
sized magnetite particles into the lymph nodes near surgically removed cancer[2]
2 Turner and rand combined the radiofrequency heating method with embolization therapy[3]
3 Meyers described how magnetic carriers  were able to accumulate small iron particles intravenously injected into the leg 
veins of dogs, using a large, externally applied horse shoe Magnet. They imagined that it might be useful for lymph 
node targeting and as a contrast agent[4]
4 Hilal  Engineered catheters with magnetic ends, and described how they could be used to deposit and selectively 
embolize arterio-venous malformations with small magnets. The use of magnetic particles for the embolization 
therapy of liver cancer followed and has recently found renewed interest[5]
5 Widder More defined spherical magnetic microspheres were made for the first time at the end of the 1970s. Their magnetic 
albumin microspheres worked well in animal experiments for tumor therapy and as magnet resonance contrast 
agents, but were not explored in clinical trials[6,7]
Table 2.
Characteristics of ferrofluids[9].
Ferrofluid characteristics
# (a) P6 iron uptake of malignant human 
glioma cells.  (b)iron uptake by normal 
human cerebral cortical neuronal cells.
# (a) BU48 iron uptake of malignant human glioma 
cells. (b) iron uptake by normal human cerebral 
cortical neuronal cells
Average particle core diameter 3.3 nm 13.1 nm
Average hydrodynamic particle diameter 50-70 nm 17 nm
Type of nanoparticle coating Dextran Aminosilan
Suspension stability as sterilized fluid Years Months
Biocompatibility High High
Formation of intracellular particle aggregates Yes No
Magnetic susceptibility 117.2 emu/g 50-100 emu/g
Surface charge Negative Highly positive
Specific absorption rate 120 mW/mg Fe 146 mW/mg Fe
Super paramagnetic Yes Yes
Table 3.
Depiction of differences in surfacted ferrofluids and ionic ferrofluids[12,13].
s.no. Surfacted ferrofluid Ionic ferrofluid
1
Surfacted ferrofluid are formed by magnetic 
particles coated with surfactant agents 
(amphiphilic Molecules, as oleic acid in order 
to prevent their aggregation.
Magnetic particles
(usually maghemite, 曘-Fe2O3, and different ferrites,MFe2O4, where M = Mn, Co, Zn, 
Cu, Ni) are obtained through a chemical precipitation method, and an acid-alkaline 
reaction between particles and the bulk keeps the surface of them electrically charged
2
Steric repulsion between particles acts as 
a physical barrier that keeps grains in the 
solution and stabilizes the colloid.
Electrostatic interaction are for stability
3
In Surfacted ferrofluid, there are steric 
repulsion forces, of short range nature
In ionic ferrofluid, long-range electrostatic interactions between charged particles give 
rise to repulsive interactions,which guarantee colloidal stability
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Table 4. 
Drugs and their polymers used in drug delivery.
s.no. Drug Polymer Application Method used Reference
1 Diclofenac sodium gelatin reduced joint swelling
Emulsification and cross 
linking
14
2 Mitomycin C
trimethylene carbonate (TMC) 
and 5,5-dimethyl trimethylene 
carbonate (DTC)
potential hepatic carcinoma therapeutics Solvent evaporation 15
3 Yttrium-90 Human serum albumin bimodal radionuclide-hyperthermia cancer therapy
Modified emulsification 
heat stabilization
16
4 alpha-chymotrypsin titanium oxide hydrolysis of N-acetyl-L-tyrosine ethyl ester immobilization 17
5 doxorubicin albumin Cancer therapy. Solvent evaporation 18
6 Indomethacin Methyl Methacrylate
selective blood detoxification, tissue engineering 
and replacement, and magnetic resonance imaging 
contrast agents
 Emulsion Solvent 
Evaporation Technique
19
7 Oxantrazole chitosan Cancer therapy
emulsion/polymer 
cross-linking/solvent 
evaporation
20
8 AMPHOTERICIN B albumin Treatment of visceral leishmaniasis. Spray drying. 21
9 5-FLUOROURACIL bovine serum albumin (BSA) tumor of hepatoma
Emulsion- ultrasound-
heat stabilization 
technique.
22
10 adriamycin albumin cytotoxic effect on tumor cells
heat-stabilized protein 
methods
22
11 vancomycin starch cytotoxic effect on tumor cells
Continuous solvent 
evaporation
23
12 clindamycin dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
23
13 azithromycin dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
23
14 aclarubicin gelatin Intravascular tumour targeting
water in oil emulsion 
polymerization
24
15 oxacyllin dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
24
16
trimethoprim/
sulfamethoxazole
dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
24
17 rifampicin dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
24
18 ofloxacin dextran
Potentiator effect on antimicrobial activity against S. 
aureus ATCC 25923 and P. aeruginosa ATCC 27853 
reference strains
Continuous solvent 
evaporation
24
19 tetracycline dextran
composite particles charged with antibiotics probably 
penetrate the bacterial cell wall and deliver the 
antibiotic in active forms to the intracellular targets.
Continuous solvent 
evaporation
24
20 penicillin dextran Potentiator effect on antimicrobial activity
Continuous solvent 
evaporation
24
21 ciprofloxacin dextran Potentiator effect on antimicrobial activity
Continuous solvent 
evaporation
24
22 gentamycin dextran
composite particles charged with antibiotics probably 
penetrate the bacterial cell wall and deliver the 
antibiotic in active forms to the intracellular targets.
Continuous solvent 
evaporation
24
23 piperacillin/tazobactam dextran Antimicrobial activity against S. aureus
Continuous solvent 
evaporation
24
24 cefepime dextran Potentiator effect on antimicrobial activity
Continuous solvent 
evaporation
24
25 aztreonam dextran Potentiator effect on antimicrobial activity
Continuous solvent 
evaporation
24
26
β-lactams 
antibiotics: Cefepime, 
Ceftriaxone,Cefuroxime 
and Cefoperazone
chitosan
Inhibiting Staphylococcus aureus and Escherichia 
coli growth.
Chemical precipitation 25
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   Sandia model and metric are used to predict the detection 
platform’s sensitivity and speed for several CONcepts of OPeration 
(CONOP): (1) agent detection (chemical or biological) in clinical 
samples, (2) botulinum toxin detection in milk, and (3) pathogen 
detection in airplane cabin air. Application of the model in these 
CONOPs indicates that the proposed platform can be optimized to 
reduce TTI, thereby minimizing the impact of Chem-bio events.
   
Figure 2. Magnetic targeting in drug and gene delivery.
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immunoassays.
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   Each bead contains a magnetic core to permit trapping for 
sample cleanup and concentration.  Bead surfaces are modified 
with Analyte Specific Reagents (ASRs). ASRs may be antibodies 
or oligonucleotides for selective analyte capture, while an internal 
quantum dot (QD) or chromophore dye facilitates bar coding. 
6.2. Solvents used for solvent evaporation method
   
   Solvent used should meet the following criteria: (1) Being 
able to dissolve the chosen polymer; (2) Being poorly soluble 
in the continuous phase; (3) Having a high volatility and a low 
boiling point; (4) Having low toxicity[28]. Polymer encapsulated 
microspheres are synthesized on the basis of a continuous solvent 
evaporation technique. A solution of polymer, drug and magnetite 
should be added to the volatile organic solvent, which forms 
Auxiliary solution on stirring. The resulting solution should be 
homogenized at stirring temperature (22-30 曟) (Figure 5 & 6). 
The magnetic microspheres will be formed in the suspension and 
should be separated by centrifugation. The product should be 
Freeze dried & stored at 4 曟[29,30]
Figure 4. Microspheres for bio detection. 
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Figure 5. Continuous solvent evaporation method.
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Figure 6. Schematic diagram of preparation of magnetic 
microspheres by solvent evaporation method.
  
Table 5
Solvents used for continuous solvent evaporation method.
Name of solvent
Vapour pressure (mbar) at 20 曟; boiling 
point (曟); solubility in water (g/L) at 20 曟
Advantages Disadvantages
Chloroform 212; 61; 8 Low solubility in water higher toxicity than dichloromethane
Dichloromethane 453; 39.7; 20
Dissolvation of most of the polymers; 
almost immiscible in water
high volatility and quite low boiling 
temperature; high toxicity
Ethyl acetate 100; 77; 90 Low toxicity
Very low vapour pressure partially 
soluble in water
Ethyl formate 259; 54; 105 Low toxicity partially soluble in water
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   Aqueous solution 
(Polymer+drug+magnetite
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Microsphere/oil suspension
Figure 7. Schematic representation of phase separation emulsion 
polymerization.
6.3. Phase separation emulsion polymerization
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 Figure 8. Factors affecting the properties of microspheres.
   Polymer encapsulated microspheres are synthesized based on 
a modified phase separation emulsion polymerization technique. 
Briefly aqueous solution of polymer, drug and magnetite should 
be added to the vegetable oil and emulsified using a magnetic 
stirrer at 1 500 rpm for 2 min. The resultant should be stabilized 
by heating at the temperature (100-150 曟). Then cross linking 
agent should be injected drop wise into the resultant emulsion 
under continuous stirring. (Figure 7). The magnetic microspheres 
will be formed in the oil suspension and then should be separated 
from oil by washing procedures. The product should be Freeze 
dried & stored at 4 曟[31].
7. Evaluation parameters for magnetic microspheres
7.1. Percentage yield of microspheres
   Thoroughly dried microspheres are collected and weighed 
accurately. The percentage yield can be calculated using formula 
given below: Percentage Yield = mass of microsphere obtained/
total weight of drug & polymer伊100[32]
7.2. Particle size analysis and particle size distribution
   a) Sieving; b) Microscopy: This method is used to determine 
particle size by using optical microscope (Meizer OPTIK) The 
measurement is  done under 450伊 (10伊 eye piece and 45伊 
objective) and100 particles are calculated; c) Coulter counter 
analysis; d) Laser Diffraction analysis. Size distribution plays an 
important role in determining the release characteristics of the 
microspheres[33].
7.3. Density
   a) Bulk density: Bulk density (ρb) (g/cm3) = M/Vb; Where, M 
= mass of powder taken, Vb = bulk volume; b) Tapped density: 
Tapped density (ρt) (g/ cm3) = M/Vt; Where, M = weight of sample 
powder, Vt = tapped volume
7.4. Flow properties
Table 6
Depiction of flow properties.
Angle of Repose (毴)
Carr榮s 
Index(%)
Hausner 
Ratio
Flow Character
25-30 <10 % 1.00-1.11 Excellent
31-35 11-15 1.12-1.18 Good
36-40 16-20 1.19-1.25 Fair
41-45 21-25 1.26-1.34 Paasable
46-55 26-31 1.35-1.45 Poor
56-65 32-37 1.46-1.59 Very Poor
>66 38 >1.60 Very Very Poor
a) Angle of repose: θ = tan-1 h/r; b) Hausner ratio = ρt/ρb; 
Where, ρt =Tapped density, ρb = bulk density
   Angle of repose is determined by using funnel method. The 
accurately weighed microspheres are taken in a funnel and then 
height of funnel is adjusted in such as way that the tip of funnel 
just touches the apex of heap of blends. The blends are allowed to 
flow through funnel freely on to surface. The diameter of powder 
cone is measured and angle of repose is calculated by using 
following equation: tanθ = h/r; Where θ - Angle of repose, h 
-height of pile, r - Radius of base. 
7.5. Shape and surface characterization
   The microspheres are mounted directly on the SEM sample 
stub, using double-sided sticking tape and coated with gold 
film (thickness 200 nm) under reduced pressure (0.001 torr) and 
photographed.
7.6. Determination of drug content
   Accurately weighed 100 mg microspheres are crushed in glass 
mortar and pestle, powder microspheres are suspended in 100 
mL of suitable solvent. After 12 h the solution was filtered and 
the filtrate was analyzed for the drug content using UV-Visible 
spectrophotometer.
7.7. Encapsulation efficiency
   Encapsulation efficiency was calculated using the 
following formula: E =Qp / Qt 伊 100; Where, E = percentage 
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of encapsulation of microspheres; Qp = quantity of drug 
encapsulated in microspheres; Qt = quantity of the drug added 
for encapsulation[34].]
7.8. Interaction study by TLC/IR
7.8.1. IR spectroscopic studies
   The IR spectra of the free drug and the microspheres were 
recorded. The identical peaks corresponding to the functional 
groups and albumin (BSA, Egg albumin, Human serum albumin) 
features confirm that neither the polymer nor the method of 
preparation has affected the drug stability.
7.8.2. Thin layer chromatographic studies
   The drug stability in the prepared microspheres can also 
be tested by the TLC method. The Rf values of the prepared 
microspheres can be compared with the Rf value of the pure drug. 
The values indicate the drug stability[35]
7.9. Surface topography by scanning electron microscopy (SEM)
   SEM of the microspheres shows the surface morphology of the 
microspheres like their shape and size
7.10. Zeta potential
   The polyelectrolyte shell is prepared by incorporating chitosan 
of different molecular weight into the W2 phase and the resulting 
particles are determined by zeta potential measurement
7.11. Stability studies
   By placing the microspheres in screw capped glass container 
and stored them at following conditions: 1. Ambient humid 
condition; 2. Room temperature (27依2) 曟; 3. Oven temperature (40
依2) 曟; 4. Refrigerator (50-80 曟).  It is carried out for 60 d and the 
drug content of the microsphere is analyzed.
8. Conclusion
   Over the years, magnetic microspheres have been investigated 
for targeted drug delivery especially magnetic targeted 
chemotherapy due to their better tumor targeting. Targeted Drug 
delivery is an effective method to assist the drug molecule to 
reach preferably to the desired site. The main advantage of this 
technique is the reduction in the dose & side effects of the drug. 
It is a challenging area for future research in the drug targeting 
so more researches, long term toxicity study, and characterization 
will ensure the improvement of magnetic drug delivery system. 
The future holds lot of promises in magnetic microspheres and 
by further study this will be developed as novel and efficient 
approach for targeted drug delivery system
Table 7
Marketed products of magnetic microspheres.
Trade name INCI name Size (毺m)
Oil abs 
(g/g)
Refractive 
index
Density 
(g/in3)
EA-209 Ethylene/acrylic acid copolymer 10.0 0.60 1.51 2.6
Flo-beads SE-3107A(soft beads A) Ethylene/Methacrylate copolymer 11.0 0.62 1.49 3.12
Flo-beads SE-3207 B(Soft beads B) Ethylene/Methacrylate copolymer 11.6 0.62 1.49 3.9
BPD-800 HDl/trimethylol hexyllactyl cross polymer (AND silica) 6.5 0.63 1.52 6.4
BPD-500 HDl/trimethylol hexyllactyl cross polymer(AND silica) 12.0 0.65 1.52 9.5
BPD-500T HDl/PPG/Polycaprolactone cross polymer (AND silica) 13.5 0.58 1.52 8.2
BPA-500 Polymethyl Methacrylate 10.0 0.55 1.49 5.2
BPA-500X Methyl Methacrylate cross polymer 7.0 0.58 1.49 6.7
MSP-822 Polymethyl Methacrylate 7.0 0.55 1.49 6.2
MSP-825 Methyl Methacrylate cross polymer 8.0 0.57 1.49 6.7
MSP-930 Methyl Methacrylate cross polymer 11.0 2.00 1.49 5.0
SUNPMMA-H Methyl Methacrylate cross polymer 11.7 0.65 1.49 NA
TR-1 NYLON-6 13.0 1.12 1.53 4.0
TR-2 NYLON-6 20.0 1.41 1.53 3.5
POMP-605 NYLON-6 6.0 1.70 1.53 3.3
POMP-610 NYLON-6 11.0 1.80 1.53 2.8
SP-10 NYLON-12 10.0 0.60 1.53 6.2
SP-10L NYLON-12 10.0 0.62 1.53 5.2
SP-500 NYLON-12 5.0 0.60 1.53 4.7
CL-2080 Polyethylene 12.0 0.60 1.51 4.0
TOSPEARL襅 1110A Polymethylsilsesquioxane 11.0 0.50 1.41 4.5
TOSPEARL襅
120A Polymethylsilsesquioxane 1.2 0.57 1.41 6.5
TOSPEARL襅
145A Polymethylsilsesquioxane 4.5 0.55 1.41 8.2
TOSPEARL襅
2000B Polymethylsilsesquioxane 5.0 0.54 1.41 8.5
TOSPEARL襅
3000 A Polymethylsilsesquioxane 5.0 0.54 1.41 7.0
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